Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 325

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Control of the Immune Response by Pro-Angiogenic Factors

Open access
Voron, Thibault, Marcheteau, Elie, Pernot, Simon, Colussi, Orianne, Tartour, Eric, Taieb, Julien, Terme, Magali·2014·Frontiers in Oncology

Abstract

The progressive conversion of normal cells into cancer cells is characterized by the acquisition of eight hallmarks. Among these criteria, the capability of the cancer cell to avoid the immune destruction has been noted. Thus, tumors develop mechanisms to become invisible to the immune system, such as the induction of immunosuppressive cells, which are able to inhibit the development of an efficient immune response. Molecules produced in the tumor microenvironment are involved in the occurrence of an immunosuppressive microenvironment. Recently, it has been shown that vascular endothelial growth factor A (VEGF-A) exhibits immunosuppressive properties in addition to its pro-angiogenic activities. VEGF-A can induce the accumulation of immature dendritic cells, myeloid-derived suppressor cells, regulatory T cells, and inhibit the migration of T lymphocytes to the tumor. Other pro-angiogenic factors such as placental growth factor (PlGF) could also participate in tumor-induced immunosuppression, but only few works have been performed on this point. Here, we review the impact of pro-angiogenic factors (especially VEGF-A) on immune cells. Anti-angiogenic molecules, which target VEGF-A/VEGFR axis, have been developed in the last decades and are commonly used to treat cancer patients. These drugs have anti-angiogenic properties but can also counteract the tumor-induced immunosuppression. Based on these immunomodulatory properties, anti-angiogenic molecules could be efficiently associated with immunotherapeutic strategies in preclinical models. These combinations are currently under investigation in cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2014.00070

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 77

  1. Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 · DOI · Paper page
  2. Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  3. Thomas, 1982, On immunosurveillance in human cancer, Yale J Biol Med, 55, 329
  4. Thomas, 1959, Discussion on Cellular and Humoral Aspects of the Hypersensitive States, 529
  5. Burnet, 1957, Cancer – a biological approach, Br Med J, 1, 779, 10.1136/bmj.1.5022.779 · DOI · Paper page
  6. Shankaran, 2001, IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity, Nature, 410, 1107, 10.1038/35074122 · DOI · Paper page
  7. Gatti, 1971, Occurrence of malignancy in immunodeficiency diseases. A literature review, Cancer, 28, 89, 10.1002/1097-0142(197107)28:189::AID-CNCR28202801173.0.CO;2-Q · doi:10.1002/1097-0142(197107)28:189::aid-cncr28202801173.0.co;2-q
  8. Birkeland, 1995, Cancer risk after renal transplantation in the Nordic countries, 1964-1986, Int J Cancer, 60, 183, 10.1002/ijc.2910600209 · DOI · Paper page
  9. Penn, 2000, Post-transplant malignancy: the role of immunosuppression, Drug Saf, 23, 101, 10.2165/00002018-200023020-00002 · DOI · Paper page
  10. Penn, 1995, Sarcomas in organ allograft recipients, Transplantation, 60, 1485, 10.1097/00007890-199560120-00020 · DOI · Paper page
  11. MacKie, 2003, Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery, N Engl J Med, 348, 567, 10.1056/NEJM200302063480620 · DOI · Paper page
  12. Strauss, 2010, Transmission of donor melanoma by organ transplantation, Lancet Oncol, 11, 790, 10.1016/S1470-2045(10)70024-3 · DOI · Paper page
  13. Galon, 2006, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 313, 1960, 10.1126/science.1129139 · DOI · Paper page
  14. Chouaib, 2012, Hypoxia promotes tumor growth in linking angiogenesis to immune escape, Front Immunol, 3, 21, 10.3389/fimmu.2012.00021 · DOI · Paper page
  15. Ferrara, 1997, The biology of vascular endothelial growth factor, Endocr Rev, 18, 4, 10.1210/edrv.18.1.0287 · DOI · Paper page
  16. Dvorak, 1995, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis harold, Am J Pathol, 146, 1029
  17. Dewerchin, 2012, PlGF: a multitasking cytokine with disease-restricted activity, Cold Spring Harb Perspect Med, 2, a011056, 10.1101/cshperspect.a011056 · DOI · Paper page
  18. Dikov, 2005, Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation, J Immunol, 174, 215, 10.4049/jimmunol.174.1.215 · DOI · Paper page
  19. Goel, 2013, VEGF targets the tumour cell, Nat Rev Cancer, 13, 871, 10.1038/nrc3627 · DOI · Paper page
  20. Hansen, 2012, Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth, J Exp Med, 209, 2001, 10.1084/jem.20111497 · DOI · Paper page
  21. Koch, 2011, Signal transduction by vascular endothelial growth factor receptors, Biochem J, 437, 169, 10.1042/BJ20110301 · DOI · Paper page
  22. Banchereau, 1998, Dendritic cells and the control of immunity, Nature, 392, 245, 10.1038/32588 · DOI · Paper page
  23. Haux, 1997, Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats, Int J Cancer, 624, 619
  24. Almand, 2000, Clinical significance of defective dendritic cell differentiation in cancer, Clin Cancer Res, 6, 1755
  25. Gabrilovich, 1996, Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells, Nat Med, 2, 1096, 10.1038/nm1096-1096 · DOI · Paper page
  26. Oyama, 1998, Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hematopoietic progenitor cells, J Immunol, 160, 1224, 10.4049/jimmunol.160.3.1224 · DOI · Paper page
  27. Lin, 2007, Placental growth factor down-regulates type 1 T helper immune response by modulating the function of dendritic cells, J Leukoc Biol, 82, 1473, 10.1189/jlb.0307164 · DOI
  28. Alfaro, 2009, Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes, Br J Cancer, 100, 1111, 10.1038/sj.bjc.6604965 · DOI · Paper page
  29. Huang, 2007, Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF, Blood, 110, 624, 10.1182/blood-2007-01-065714 · DOI · Paper page
  30. Zea, 2004, l-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes, Cell Immunol, 232, 21, 10.1016/j.cellimm.2005.01.004 · DOI · Paper page
  31. Rodriguez, 2007, l-arginine availability regulates T-lymphocyte cell-cycle progression, Blood, 109, 1568, 10.1182/blood-2006-06-031856 · DOI · Paper page
  32. Mazzoni, 2002, Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism, J Immunol, 168, 689, 10.4049/jimmunol.168.2.689 · DOI · Paper page
  33. Fischer, 2001, Activation of cGMP-dependent protein kinase Ibeta inhibits interleukin 2 release and proliferation of T cell receptor-stimulated human peripheral T cells, J Biol Chem, 276, 5967, 10.1074/jbc.M009781200 · DOI
  34. Kusmartsev, 2004, Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species, J Immunol, 172, 989, 10.4049/jimmunol.172.2.989 · DOI · Paper page
  35. Li, 2009, Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1, J Immunol, 182, 240, 10.4049/jimmunol.182.1.240 · DOI · Paper page
  36. Hoechst, 2009, Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor, Hepatology, 50, 799, 10.1002/hep.23054 · DOI · Paper page
  37. Gabrilovich, 1998, Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo, Blood, 92, 4150, 10.1182/blood.V92.11.4150 · DOI · Paper page
  38. Almand, 2001, Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer, J Immunol, 166, 678, 10.4049/jimmunol.166.1.678 · DOI · Paper page
  39. Huang, 2006, Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host, Cancer Res, 66, 1123, 10.1158/0008-5472.CAN-05-1299 · DOI · Paper page
  40. Yang, 2006, CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells, Cancer Res, 66, 6807, 10.1158/0008-5472.CAN-05-3755 · DOI · Paper page
  41. Serafini, 2008, Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells, Cancer Res, 68, 5439, 10.1158/0008-5472.CAN-07-6621 · DOI · Paper page
  42. Ghiringhelli, 2005, Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation, J Exp Med, 202, 919, 10.1084/jem.20050463 · DOI · Paper page
  43. Hanada, 2000, Prognostic value of tumor-associated macrophage count in human bladder cancer, Int J Urol, 7, 263, 10.1046/j.1442-2042.2000.00190.x · DOI · Paper page
  44. Lissbrant, 2000, Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival, Int J Oncol, 17, 445
  45. Salvesen, 1999, Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas, Int J Cancer, 84, 538, 10.1002/(SICI)1097-0215(19991022)84:5538::AID-IJC173.3.CO;2-2 · doi:10.1002/(sici)1097-0215(19991022)84:5538::aid-ijc173.3.co;2-2
  46. Leek, 1996, Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma, Cancer Res, 56, 4625
  47. Linde, 2012, Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages, J Pathol, 227, 17, 10.1002/path.3989 · DOI · Paper page
  48. Lewis, 2007, Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2, Breast Cancer Res, 9, 209, 10.1186/bcr1679 · DOI
  49. Ohm, 2003, VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression, Blood, 101, 4878, 10.1182/blood-2002-07-1956 · DOI · Paper page
  50. Prévost-Blondel, 1998, Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo, J Immunol, 161, 2187, 10.4049/jimmunol.161.5.2187 · DOI · Paper page
  51. Hermans, 1998, Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors, Cancer Res, 58, 3909
  52. Lee, 1999, Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients, Nat Med, 5, 677, 10.1038/9525 · DOI · Paper page
  53. Romero, 1998, Ex vivo staining of metastatic lymph nodes by class i major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes, J Exp Med, 188, 10.1084/jem.188.9.1641 · DOI · Paper page
  54. Rosenberg, 2005, Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma, J Immunol, 175, 6169, 10.4049/jimmunol.175.9.6169 · DOI · Paper page
  55. Hamzah, 2008, Vascular normalization in Rgs5-deficient tumours promotes immune destruction, Nature, 453, 410, 10.1038/nature06868 · DOI · Paper page
  56. Ziogas, 2012, VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2, Int J Cancer, 130, 857, 10.1002/ijc.26094 · DOI · Paper page
  57. Gavalas, 2012, VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2, Br J Cancer, 107, 1869, 10.1038/bjc.2012.468 · DOI · Paper page
  58. Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655 · DOI · Paper page
  59. Miller, 2007, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med, 357, 2666, 10.1056/NEJMoa072113 · DOI · Paper page
  60. Gabrilovich, 1999, Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function, Clin Cancer Res, 5, 2963
  61. Kusmartsev, 2008, Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma, J Immunol, 181, 346, 10.4049/jimmunol.181.1.346 · DOI · Paper page
  62. Xin, 2009, Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells, Cancer Res, 69, 2506, 10.1158/0008-5472.CAN-08-4323 · DOI · Paper page
  63. Cao, 2011, Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model, Lab Invest, 91, 598, 10.1038/labinvest.2010.205 · DOI
  64. Ko, 2009, Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients, Clin Cancer Res, 15, 2148, 10.1158/1078-0432.CCR-08-1332 · DOI · Paper page
  65. Abe, 2010, Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice, Int Immunopharmacol, 10, 140, 10.1016/j.intimp.2009.09.023 · DOI
  66. Chen, 2013, Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity, Int J Cancer, 134, 319, 10.1002/ijc.28362 · DOI
  67. Kujawski, 2010, Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects, Cancer Res, 70, 9599, 10.1158/0008-5472.CAN-10-1293 · DOI
  68. Adotevi, 2010, A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients, J Immunother, 33, 991, 10.1097/CJI.0b013e3181f4c208 · DOI · Paper page
  69. Nagai, 2012, Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma, Clin Dev Immunol, 2012, 607851, 10.1155/2012/607851 · DOI
  70. Shrimali, 2010, Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer, Cancer Res, 70, 6171, 10.1158/0008-5472.CAN-10-0153 · DOI · Paper page
  71. Terme, 2012, Modulation of immunity by antiangiogenic molecules in cancer, Clin Dev Immunol, 2012, 492920, 10.1155/2012/492920 · DOI
  72. Tartour, 2011, Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy, Cancer Metastasis Rev, 30, 83, 10.1007/s10555-011-9281-4 · DOI · Paper page
  73. Bose, 2011, Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination, Int J Cancer, 129, 2158, 10.1002/ijc.25863 · DOI
  74. Farsaci, 2012, Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy, Int J Cancer, 130, 1948, 10.1002/ijc.26219 · DOI
  75. Jaini, 2014, Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy, Int J Cancer, 134, 1695, 10.1002/ijc.28488 · DOI
  76. Dall’Oglio, 2011, Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy, Int Braz J Urol, 37, 180, 10.1590/S1677-55382011000200004 · doi:10.1590/s1677-55382011000200004
  77. Bhatia, 2014, Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study, J Immunother Cancer, 2, 2, 10.1186/2051-1426-2-2 · DOI

Cited by

See all 325

Metadata

Authors
Voron, T., Marcheteau, E., Pernot, S., Colussi, O., Tartour, E., Taieb, J., & Terme, M.
Venue
Frontiers in Oncology
Published
2014-04-02
Volume
4
Pages
70-70
ISSN
2234-943X (ISSN-L)
OpenAlex
W2169435545
Cited by
325
References
19
FWCI
8.52
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Control of the Immune Response by Pro-Angiogenic Factors. https://app.cochat.ai/papers/10.3389/fonc.2014.00070
The paper
Voron, T., Marcheteau, E., Pernot, S., Colussi, O., Tartour, E., Taieb, J., & Terme, M. (2014). Control of the Immune Response by Pro-Angiogenic Factors. Frontiers in Oncology. https://doi.org/10.3389/fonc.2014.00070

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.